Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes

Trends in Endocrinology and Metabolism

Volumn 11, Issue 6, 2000, Pages 212-217

  Moller, David E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADIPOSE TISSUE; DOWN REGULATION; DYSLIPIDEMIA; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; LIPOLYSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REVIEW; RODENT; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; MICE; MICE, TRANSGENIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033867178     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00272-1     Document Type: Review

References (51)

1. Beutler B., Cerami A. Cachectin (tumor necrosis factor). a macrophage hormone governing cellular metabolism and inflammatory response Endocr. Rev. 9:1988;57-66.
2. Torti F.M.et al. A macrophage factor inhibits adipocyte gene expression. an in vitro model of cachexia Science. 229:1985;867-869.
3. Hotamisligil G.S.et al. Adipose tissue expression of tumor necrosis factor alpha. direct role in obesity-linked insulin resistance Science. 259:1993;87-90.
4. Morin C.L.et al. High fat diets elevate adipose tissue-derived tumor necrosis factor-α activity. Endocrinology. 138:1997;4665-4671.
5. Houseknecht K.L.et al. Secretion of leptin and TNFα by the adipocyte in vitro. regulation with genetic and dietary-induced obesity J. Anim. Sci. 74(Suppl. 1):1996;150. (abstr.).
6. Kern P.A.et al. The expression of tumor necrosis factor in human adipose tissue. regulation by obesity, weight loss, and relationship to lipoprotein lipase J. Clin. Invest. 95:1995;2111-2119.
7. Hotamisligil G.S.et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95:1995;2409-2415.
8. Sewter C.P.et al. Regulation of tumour necrosis factor-α release from human adipose tissue in vitro. J. Endocrinol. 163:1999;33-38.
9. Zinman B.et al. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 84:1999;272-278.
10. Gonzalez F.et al. Elevated serum levels of tumor necrosis factor alpha in normal weight women with polycystic ovary syndrome. Metab. Clin. Exp. 48:1999;437-441.
11. Tsigos C.et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metab. Clin. Exp. 48:1999;1332-1335.
12. Saghizadeh M.et al. The expression of TNF-α by human muscle. relationship to insulin resistance J. Clin. Invest. 97:1996;1111-1116.
13. Fernandez-Real J.M.et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 47:1998;1757-1762.
14. Norman R.A.et al. Linkage between obesity and a marker near the tumor necrosis-α locus in Pima Indians. J. Clin. Invest. 96:1995;158-162.
15. Walston J.et al. Tumor necrosis factor-α 238 and 308 polymorphisms do not associate with traits related to obesity and insulin resistance. Diabetes. 48:1999;2096-2098.
16. Hotamisligil G.S.et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 274:1996;1377-1379.
17. Spiegelman B.M., Hotamisligil G.S. Through thick and thin. wasting, obesity, and TNFα Cell. 73:1993;625-627.
18. Grunfeld C., Feingold K.R. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 3:1991;143-158.
19. Lang C.H.et al. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 130:1992;43-52.
20. Evans A.D.et al. Tumor necrosis factor enhances glucose uptake by peripheral tissues. Am. J. Physiol. 257:1989;R1182-R1189.
21. Van der Poll T.et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol. 261:1991;E457-E465.
22. Cheung A.T.et al. An in vivo model for the elucidation of the mechanism of tumor necrosis factor-α induced insulin resistance. Endocrinology. 139:1998;4928-4935.
23. Lopez-Soriano F.J.et al. Anti-TNF treatment does not reverse the abnormalities in lipid metabolism of the obese Zucker rat. Am. J. Physiol. 35:1997;E656-E660.
24. Ventre J.et al. Targeted disruption of the tumor necrosis factor-α gene. metabolic consequences in obese and non-obese mice Diabetes. 46:1997;1526-1531.
25. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor α a key component of the obesity-diabetes link Diabetes. 43:1994;1271-1278.
26. Uysal K.T.et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 389:1997;610-614.
27. Schreyer S.A.et al. Obesity and diabetes in TNF-α receptor-deficient mice. J. Clin. Invest. 102:1998;402-411.
28. Zhang B.et al. Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the anti-adipogenic effects of tumor necrosis factor-α Mol. Endocrinol. 10:1996;1457-1466.
29. Szalkowski D.et al. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136:1995;1474-1481.
30. Stephens J.M., Pekala P.H. Transcriptional repression of the GLUT4 and c/EBP genes in 3T3-L1 cells by tumor necrosis factor-alpha. J. Biol. Chem. 266:1991;21839-21845.
31. Hotamisligil G.S.et al. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4854-4858.
32. Liu L.S.et al. Tumor necrosis factor-α acutely inhibits insulin signaling in human adipocytes. Diabetes. 47:1998;515-522.
33. Nolte L.A.et al. Short-term exposure to tumor necrosis factor-α does not affect insulin-stimulated glucose uptake in skeletal muscle. Diabetes. 47:1998;721-726.
34. Furnsinn C.et al. Acute and chronic exposure to tumor necrosis factor-α fails to affect insulin-stimulated glucose metabolism of isolated rat soleus muscle. Endocrinology. 138:1997;2674-2679.
35. Spiegelman B.M. PPAR-gamma. adipogenic regulator and thiazolidinedione receptor Diabetes. 47:1998;507-514.
36. Barroso I.et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature. 402:1999;880-883.
37. Hofmann C.et al. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134:1994;264-270.
38. Okuno A.et al. Troglitazone increases the number of small adipocytes without the changes of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1998;1354-1361.
39. Thieringer R.et al. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to LPS in vitro or in vivo. J. Immunol. 164:2000;1046-1054.
40. Souza S.C.et al. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-α a potential new insulin sensitizing mechanism for thiazolidinediones Diabetes. 47:1998;691-695.
41. Miles P.D.G.et al. TNF-alpha induced insulin resistance in vivo and its prevention by troglitazone. Diabetes. 46:1997;1678-1683.
42. Hotamisligil G.S.et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science. 271:1996;665-668.
43. Guo D., Donner D.B. Tumor necrosis factor promotes phosphoryl- ation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J. Biol. Chem. 271:1996;615-618.
44. Feinstein R.et al. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 268:1993;26055-26058.
45. Kroder G.et al. Tumor necrosis factor-α and hyperglycemia-induced insulin resistance. J. Clin. Invest. 97:1996;1471-1477.
46. Paz K.et al. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem. 272:1997;29911-29918.
47. Stephens J.M.et al. Tumor necrosis factor-α induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT 4 expression without a loss of insulin receptor-mediated signal transduction. J. Biol. Chem. 272:1997;971-976.
48. Peraldi P.et al. Tumor necrosis factor-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J. Biol. Chem. 271:1996;13018-13022.
49. Xu H.et al. Transmembrane tumor necrosis factor-α inhibits adipocyte differentiation by selectively activating TNF receptor 1. J. Biol. Chem. 274:1999;26287-26295.
50. Kanety H.et al. Sphingomyelinase and ceramide suppress insulin-induced tyrosine kinase phosphorylation of the insulin receptor substrate-1. J. Biol. Chem. 271:1996;9895-9897.
51. Ofei F.et al. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 45:1996;881-885.